Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PRLD

PRLD - Prelude Therapeutics Incorporated Stock Price, Fair Value and News

$1.39+0.04 (+2.96%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

PRLD Price Action

Last 7 days

-16.8%

Last 30 days

-65.1%

Last 90 days

21.9%

Trailing 12 Months

41.8%

PRLD RSI Chart

PRLD Valuation

Market Cap

87.4M

Price/Earnings (Trailing)

-0.78

Price/Sales (Trailing)

13.11

Price/Free Cashflow

-0.87

PRLD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PRLD Fundamentals

PRLD Revenue

Revenue (TTM)

7.0M

PRLD Earnings

Earnings (TTM)

-111.8M

Earnings Growth (Yr)

38.88%

Earnings Growth (Qtr)

36.84%

PRLD Profitability

Return on Equity

-190.95%

Return on Assets

-117.96%

Free Cashflow Yield

-114.77%

PRLD Investor Care

Shares Dilution (1Y)

14.23%

Diluted EPS (TTM)

-1.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20240007.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Prelude Therapeutics Incorporated

PRLD
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma. The company is also developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 2 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
 CEO
 WEBSITEhttps://preludetx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES122

Prelude Therapeutics Incorporated Frequently Asked Questions

What is the ticker symbol for Prelude Therapeutics Incorporated? What does PRLD stand for in stocks?

PRLD is the stock ticker symbol of Prelude Therapeutics Incorporated. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Prelude Therapeutics Incorporated (PRLD)?

As of Wed Dec 03 2025, market cap of Prelude Therapeutics Incorporated is 87.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRLD stock?

You can check PRLD's fair value in chart for subscribers.

Is Prelude Therapeutics Incorporated a good stock to buy?

The fair value guage provides a quick view whether PRLD is over valued or under valued. Whether Prelude Therapeutics Incorporated is cheap or expensive depends on the assumptions which impact Prelude Therapeutics Incorporated's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRLD.

What is Prelude Therapeutics Incorporated's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, PRLD's PE ratio (Price to Earnings) is -0.78 and Price to Sales (PS) ratio is 13.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRLD PE ratio will change depending on the future growth rate expectations of investors.